EGFR and neoplasm: Moreover, FGF-2 leaking out from gefitinib-treated NSLC cells was proposed as a survival factor for tumor cells that remained alive after the first exposure of EGFR-TKIs and further maintained their resistance to EGFR-TKIs [42,43].